IDEXX Laboratories Stock Price, News & Analysis

IDEXX (NASDAQ: IDXX) launched the ImageVue DR50 Plus digital imaging system on January 15, 2026, a connected veterinary radiography solution offering AI-powered imaging and integrated workflows. The system claims up to 25% lower radiation versus IDEXX’s prior DR50 and up to 60% lower radiation versus other veterinary systems, plus a new 17" x 17" panel option. Features include automated image optimization, irradiated side sampling to reduce retakes, IDEXX Web PACS integration, AI hanging protocols and vertebral heart scores, direct Telemedicine submission to 160+ board-certified specialists, and a claimed >45% reduction in clicks to submit cases. Available in the United States and Canada.

IDEXX (NASDAQ: IDXX) announced expansion of its Cancer Dx Panel to include canine mast cell tumor detection, available mid‑year 2026 in the United States and Canada, and rollout of inVue Dx FNA cytology with mast cell tumor detection beginning late Q4 2025 in the U.S. Combined, mast cell tumor and lymphoma detection will address over one‑third of canine cancer cases. The Cancer Dx Panel is used by >5,500 practices in North America and can detect lymphoma up to eight months before clinical signs. Cancer Dx results return in 2–3 days (Canada 2–4 days). inVue Dx FNA offers rapid, slide‑free in‑clinic cytology with optional expert pathologist review.

IDEXX (NASDAQ: IDXX) announced a planned CEO succession: Michael Erickson, PhD, will become President and CEO effective May 12, 2026, and will join the Board upon assuming the role. Current President and CEO Jonathan (Jay) Mazelsky will transition to Executive Chair at that time and has said he will retire following the Company’s annual meeting of shareholders in May 2027. The company described an extended transition with Mazelsky working closely with Erickson to support continuity. Erickson joined IDEXX in 2011 and has held senior roles across diagnostics, software, strategy, and corporate accounts.

IDEXX Laboratories (NASDAQ: IDXX) will release its 2025 fourth quarter and full year financial results on Monday, February 2, 2026 before market open. An analyst conference call will begin at 8:30 a.m. ET that day and will be available via a live webcast, telephone, and an archived webcast posted after 1:00 p.m. ET that will remain available for one year.

Investors can access the live webcast, a transcript of prepared remarks, and a Q4 2025 Earnings Snapshot from the company investor site at www.idexx.com/investors. To join the live call by phone dial 1-800-330-6730 or 1-213-279-1575 and reference passcode 263206.

Summary not available.

Bonsai Health named Rick Trefzger Chief Revenue Officer on October 16, 2025, after nearly 11 years at Modernizing Medicine and a recent vice president role at IDEXX (Nasdaq: IDXX). Trefzger will oversee all go-to-market functions including sales, marketing, and business development to expand Bonsai’s presence across medical specialties.

The appointment follows a $7 million seed raise led by Bonfire Ventures and Wonder Ventures as Bonsai scales its agentic AI platform to reduce administrative burden and improve patient outcomes.

IDEXX Laboratories (NASDAQ: IDXX) will release its 2025 third quarter financial results on Monday, November 3, 2025 before market open. An analyst conference call will begin at 8:30 a.m. ET that day.

Investors can access a live webcast, transcript of prepared remarks, and the Q3 2025 Earnings Snapshot at www.idexx.com/investors. An archived webcast will be available after 1:00 p.m. ET on November 3 and will remain online for one year. The live call is also available by telephone at 1-800-330-6730 or 1-213-279-1575 using passcode 300701.

IDEXX Laboratories (NASDAQ: IDXX) announced the election of Karen Peacock to its Board of Directors, effective October 6, 2025. The board chair said Peacock brings deep B2B, SaaS and AI experience.

Background highlights: former CEO of Intercom; ~14 years at Intuit including SVP of Small Business; current lead independent director at Dropbox; Harvard BA and Stanford MBA. Peacock said she looks forward to supporting IDEXX's diagnostics, software and AI efforts for veterinary practices.

IDEXX Laboratories (NASDAQ: IDXX), a leader in pet healthcare innovation, announced its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference. CEO Jay Mazelsky and CFO Andrew Emerson will engage in a fireside chat on September 9, 2025, from 1:50 PM to 2:25 PM ET.

Investors can access the live audio webcast through the company's investor relations website at www.idexx.com/investors. An archived version of the presentation will also be made available after the event.